Interest in the dissociative anesthetic ketamine continues to be strong as a therapy for treatment-resistant depression and similar conditions. But the enthusiasm surrounding the drug is likely higher than the quality of evidence supporting its use to treat severe depression. Research into the drug’s potential to treat depression, however, is ramping up. One small study…
What the ketamine boom could mean for pharma
Demand for ketamine has surged in recent years with growing interest in its off-label use for treating depression, anxiety and PTSD. Ketamine has “shown to be very effective,” said Linnea Butler, founder and CEO of Bay Area Mental Health (Campbell, California), which recently began offering ketamine-assisted psychotherapy. Also this week, Pasithea Therapeutics Corp. (NSDQ:KTTA), announced…